A large real-world clinical trial in Brazil called SAVE is testing whether esketamine — a nasal-spray version of the anesthetic ketamine, already approved for depression — can quickly reduce the urge to attempt suicide in people in crisis. Results are expected around November 2026, and the prediction is that the numbers will show a clear, meaningful benefit. This could change emergency mental health care globally.
Acute anti-suicidal signals for esketamine replicate consistently across trials. Pragmatic municipal design favors real-world effect detection. The data is undeniable — delay costs lives.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →